ESMO Breast 2025 | PALLAS: assessing clinician-graded AEs & QoL in HR+/HER2- breast cancer

Vesna Bjelic-Radisic • 9 May 2025

ESMO Breast 2025

Breast Cancer

PALLAS

Vesna Bjelic-Radisic, MD, PhD, Helios University Hospital Wuppertal, Wuppertal, Germany, discusses an analysis from the Phase III PALLAS trial (NCT02513394), which evaluated the relationship between clinician-graded adverse events (AEs) and patient-reported quality of life (QoL) in early HR+/HER2- breast cancer. Despite consistent data collection, correlations between clinician assessments and patient-reported outcomes were generally weak. Low agreement was observed for several symptoms, including pain, nausea, and insomnia. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.